Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Seeks Shareholder Nod for Rs. 16.51 Cr Preferential Issue
FUNDRAISE
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 10 Jun 2026, 06:58 PM IST · BSE ID: a55f511c-6f35-4a50-81b4-0135408adcf8
View Original BSE Filing (PDF)
💡
In Simple Terms
The company needs shareholder permission to re-issue warrants at a new price after a deadline passed.
🤖 AI Summary
- Shukra Pharmaceuticals seeks shareholder approval for a preferential issue of 46,43,000 warrants.
- The issue aims to re-price previously approved warrants at Rs. 35.56 per warrant.
- Total funds to be raised are approximately Rs. 16,51,05,080 for the warrant allotment.
- An Extra-Ordinary General Meeting is scheduled for July 6, 2026, to seek approval.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Convertible Equity Warrants
46,43,000
Revised Issue Price Per Warrant
Rs.35.56
Total Funds to be Raised
Rs.16,51,05,080
Extra-Ordinary General Meeting Date
July 06, 2026
🏢 How This Affects the Company
This action allows the company to proceed with a previously planned equity-raising instrument, potentially strengthening its capital base.
The preferential issue will raise Rs. 16,51,05,080 in cash consideration upon warrant exercise, impacting the company's cash reserves.
Failure to obtain shareholder approval could delay or cancel this specific capital-raising initiative.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must attend or vote by proxy at the Extra-Ordinary General Meeting on July 6, 2026, to approve the preferential issue.
👤
Who Is Affected
All shareholders of record will have their voting rights exercised at the EGM concerning the preferential issue of warrants.
🔍
Management Signal
Management is demonstrating intent to utilize approved capital-raising instruments despite an initial procedural delay.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of EGM on July 6, 2026, for preferential issue approval.
Board meeting to approve allotment post EGM approval.
Confirmation of funds received from warrant exercise.
MEDIUM RISK
Shareholder approval is a prerequisite for the preferential issue to proceed.
💡 Investor Takeaway
Shukra Pharmaceuticals will hold an EGM on July 6, 2026, to seek approval for a preferential issue of 46,43,000 warrants at Rs. 35.56 each, aiming to raise Rs. 16,51,05,080.
⚖️ Strengths & Concerns
✅ Positives
- Company is seeking shareholder approval for a preferential issue totaling Rs. 16,51,05,080.
- Revised issue price of Rs. 35.56 per warrant is determined as per SEBI ICDR Regulations.
⚠️ Concerns
- Original warrant allotment deadline was missed, necessitating fresh shareholder approval.
- Dependence on shareholder approval introduces uncertainty regarding the timing of fund inflow.
📅 Company Track Record
Previously, Shukra Pharmaceuticals allotted 17.35 lakh shares via preferential warrants in May 2026, raising Rs. 4.42 Cr.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is Shukra Pharmaceuticals proposing to do?
The company's Board approved seeking shareholder approval for a preferential issue of 46,43,000 convertible equity warrants.
What is the total value of the proposed preferential issue?
The preferential issue of warrants is for a total of Rs. 16,51,05,080.
What is the revised issue price for the warrants?
The revised issue price for each convertible equity warrant has been determined at Rs.35.56.
When will the shareholders vote on this proposal?
An Extra-Ordinary General Meeting is scheduled to be held on Monday, July 06, 2026, for shareholders to vote.
Why is fresh shareholder approval needed for these warrants?
The allotment of the warrants could not be completed within the prescribed period, requiring fresh shareholder approval as per SEBI regulations.
Questions based on this BSE filing only. For information purposes.